Background: The Repeat Expansion Diseases are caused by intergenerational expansions of a specific tandem repeat. More than 20 such diseases that belong to this group have been identified thus far. The Fragile X-related disorders (FXDs) arise from expansion of a CGG.CCG-repeat in the 5' UTR of the X-linked FMR1 gene. Carriers of alleles with 55-200 repeats, so-called premutation (PM) alleles, are at risk for a neurodegenerative disorder, Fragile X-associated tremor/ataxia syndrome (FXTAS) and a form of ovarian dysfunction known as FX-associated primary ovarian insufficiency (FXPOI). Furthermore, in females, the premutation allele can undergo expansion on intergenerational transfer that can result in their children having alleles with >200 repeats. This expanded allele is known as a full mutation (FM) and individuals who inherit such alleles almost always have Fragile X syndrome (FXS), which is the leading heritable cause of intellectual disability. FM alleles become silenced. This results in a deficiency of the protein product of this gene, FMRP, which is involved in the regulation of translation of a subset of mRNAs. The FMRP deficiency in brain results in aberrant dendritic spine morphology and a defective response to synaptic activation. The mechanism of gene silencing is unknown, but may show parallels to Friedreich ataxia, a related disorder that also shows repeat-mediated gene silencing. Progress report: In addition to our ongoing work on FXPOI using a mouse model we developed, we have used induced pluripotent stem cells (iPSCs) and a patient-derived embryonic stem cell (ESC) line to study the mechanism of gene silencing that is responsible for FXS. Our findings this year include the identification of small molecules that produce sustained FMR1 gene expression in FX cells treated with a single dose of 5-azadeoxycytidine. The importance of this finding is that it demonstrates that despite the expression of the FMR1 transcript that we previously showed was responsible for gene silencing, silencing can still be prevented by blocking the epigenetic events that are triggered by the FMR1 mRNA. One class of molecules that were effective at prolonging gene expression are inhibitors of EZH2, the catalytic component of the Polycomb Repressive Complex 2 (PRC2) that we had previously hypothesized to be important for Fragile X gene silencing. The second class of molecules interact directly with the CGG-RNA and we hypothesize that they act by preventing binding to chromatin repressors.In the course of doing this work we also developed a set of tools for analyzing repeat length, AGG interruption patterns and the methylation status of the FMR1 gene. These tools, which are robust and inexpensive, should allow the routine monitoring of these parameters in studies of the effect of PM and FM alleles on early embryonic development. Without such tools it is impossible to distinguish between bona fide developmentally regulated changes and artifacts arising from the instability in repeat number and methylation commonly associated with these cells

Project Start
Project End
Budget Start
Budget End
Support Year
20
Fiscal Year
2016
Total Cost
Indirect Cost
Name
U.S. National Inst Diabetes/Digst/Kidney
Department
Type
DUNS #
City
State
Country
Zip Code
Hayward, Bruce E; Usdin, Karen (2017) Improved Assays for AGG Interruptions in Fragile X Premutation Carriers. J Mol Diagn 19:828-835
Hayward, Bruce E; Kumari, Daman; Usdin, Karen (2017) Recent advances in assays for the fragile X-related disorders. Hum Genet 136:1313-1327
Zhou, Yifan; Kumari, Daman; Sciascia, Nicholas et al. (2016) CGG-repeat dynamics and FMR1 gene silencing in fragile X syndrome stem cells and stem cell-derived neurons. Mol Autism 7:42
Hayward, Bruce E; Zhou, Yifan; Kumari, Daman et al. (2016) A Set of Assays for the Comprehensive Analysis of FMR1 Alleles in the Fragile X-Related Disorders. J Mol Diagn 18:762-774
Conca Dioguardi, Carola; Uslu, Bahar; Haynes, Monique et al. (2016) Granulosa cell and oocyte mitochondrial abnormalities in a mouse model of fragile X primary ovarian insufficiency. Mol Hum Reprod 22:384-96
Kumari, Daman; Usdin, Karen (2016) Sustained expression of FMR1 mRNA from reactivated fragile X syndrome alleles after treatment with small molecules that prevent trimethylation of H3K27. Hum Mol Genet 25:3689-3698
Kumari, Daman; Swaroop, Manju; Southall, Noel et al. (2015) High-Throughput Screening to Identify Compounds That Increase Fragile X Mental Retardation Protein Expression in Neural Stem Cells Differentiated From Fragile X Syndrome Patient-Derived Induced Pluripotent Stem Cells. Stem Cells Transl Med 4:800-8
Usdin, Karen; Kumari, Daman (2015) Repeat-mediated epigenetic dysregulation of the FMR1 gene in the fragile X-related disorders. Front Genet 6:192
Sherman, Stephanie L; Curnow, Eliza C; Easley, Charles A et al. (2014) Use of model systems to understand the etiology of fragile X-associated primary ovarian insufficiency (FXPOI). J Neurodev Disord 6:26
Usdin, Karen; Hayward, Bruce E; Kumari, Daman et al. (2014) Repeat-mediated genetic and epigenetic changes at the FMR1 locus in the Fragile X-related disorders. Front Genet 5:226

Showing the most recent 10 out of 17 publications